Pfizer weight loss pill joins list of obesity drug flops

Pfizer weight loss pill joins list of obesity drug flops

Sopa Images | Lightrocket | Getty Images Pfizer’s twice-daily version of its experimental weight loss pill has now joined a long list of other scrapped drugs that aimed to treat obesity but came with unintended consequences.  The drugmaker on Friday said it will stop developing the twice-daily treatment, danuglipron, after obese patients taking the drug … Read more

Roche enters obesity market with Carmot takeover

Roche enters obesity market with Carmot takeover

BRAZIL – 2021/11/26: In this photo illustration a F. HoffmannLa Roche AG logo is seen on a screen and a hand holding a pill. (Photo Illustration by Rafael Henrique/SOPA Images/LightRocket via Getty Images) Sopa Images | Lightrocket | Getty Images Swiss pharmaceuticals giant Roche is set to acquire anti-obesity drug developer Carmot Therapeutics, becoming the … Read more

Eli Lilly weight loss drug Zepbound available at U.S. pharmacies

Eli Lilly weight loss drug Zepbound available at U.S. pharmacies

The FDA approves Eli Lilly’s Zepbound, a weight loss drug similar to Ozempic and Wegovy. Courtesy: Eli Lilly Eli Lilly on Tuesday said its recently approved weight loss treatment Zepbound is now available at pharmacies across the U.S., serving as an alternative to rival obesity drugs such as Wegovy that are facing supply issues.  Zepbound … Read more

Free ChatGPT may incorrectly answer drug questions, study says

Free ChatGPT may incorrectly answer drug questions, study says

Harun Ozalp | Anadolu | Getty Images The free version of ChatGPT may provide inaccurate or incomplete responses — or no answer at all — to questions related to medications, which could potentially endanger patients who use OpenAI’s viral chatbot, a new study released Tuesday suggests. Pharmacists at Long Island University who posed 39 questions … Read more

CVS to change how it prices prescription drugs

CVS to change how it prices prescription drugs

A person walks by a CVS pharmacy store in Manhattan, New York, U.S., November 15, 2021. Andrew Kelly | Reuters CVS Health on Tuesday said it will revamp how it prices prescription drugs and scrap a complex model that typically sets how much pharmacies get reimbursed and what patients pay for those medications. The new … Read more

U.S. poised to approve breakthrough treatment

U.S. poised to approve breakthrough treatment

At age 19, Joe Tsogbe underwent his first hip replacement. In his 20s, he averaged about nine hospitalizations a year. By his 30s, that rose to more than a dozen.  All the result of sickle cell disease, an inherited blood disorder where a genetic mutation causes normally full-moon shaped red blood cells to form into … Read more

AbbVie to acquire Cerevel Therapeutics for $8.7 billion

AbbVie to acquire Cerevel Therapeutics for .7 billion

AbbVie on Wednesday said it will acquire neuroscience drugmaker Cerevel Therapeutics for roughly $8.7 billion.  Under the terms of the deal, AbbVie will pay $45 per share for Cerevel. AbbVie said it expects to complete the acquisition in the middle of 2024.  Shares of Cerevel jumped 16% after the close Wednesday to nearly $43 per … Read more

Biden administration asserts power to seize drug patents

Biden administration asserts power to seize drug patents

President Joe Biden speaks about protecting Social Security, Medicare, and lowering prescription drug costs, during a visit to OB Johnson Park and Community Center, in Hallandale Beach, Florida, on Nov. 1, 2022. Kevin Lamarque | Reuters The Biden administration on Thursday opened the door to seizing the patents of certain costly medications from drugmakers in … Read more

First CRISPR gene-editing treatment approved in U.S.

First CRISPR gene-editing treatment approved in U.S.

The U.S. Food and Drug Administration on Friday approved the country’s first gene-editing treatment, Casgevy, for use in patients with sickle cell disease. The approval comes about a decade after the discovery of CRISPR technology for editing human DNA, representing a significant scientific advancement. Yet reaching the tens of thousands of people who could benefit … Read more

Exxon sees big earnings boost from cost cuts, will increase share buybacks after Pioneer deal closes

Exxon sees big earnings boost from cost cuts, will increase share buybacks after Pioneer deal closes

Darren Woods, chairman and chief executive officer of Exxon Mobil Corp., Brendan McDermid | Reuters Exxon Mobil said Wednesday its expects earnings to more than double through 2027 relative to 2019 as the energy giant moves forward with a slew of cost-cutting measures. Exxon said it’s on track to grow its earnings and cash flow … Read more